You carry every pharmacy claim directly: no insurer buffer, no pooled risk. StreamRX shows you where your drug spend has lower-cost options, in a plain-language report your benefits team, CFO, and broker can act on.
A 10,000-member commercial plan typically spends more than $20 million a year on prescriptions, and GLP-1s keep pushing that higher. Finding even 3 to 5% is real money, often without changing your PBM.
Estimate your plan's number with our savings calculator →
See estimates for real self-funded employers in our free plan lookup →
Illustrative estimates based on typical commercial plan drug spend (about $2,400 per member per year in 2025). Your results depend on your claims mix, PBM contract terms, and rebate arrangements.
We compare what your plan pays against generic equivalents, therapeutic alternatives, and public price benchmarks, then flag what it would take to act on each one.
Same active ingredient, significantly lower cost.
Clinically comparable drugs in the same class, reviewed by a pharmacist.
What your plan pays compared with public benchmarks, to spot overpayment and markup.
Which options need a PBM conversation before you can use them.
No conflicts, no black boxes. Just a clear view of your drug spend from a team that knows how pharmacy pricing really works.
No PBM compensation of any kind: no commissions, no rebate sharing, no referral fees.
Every alternative is checked by a pharmacist, backed by a team with 40+ years in pharmacy.
We never take a percentage of savings, so our recommendations aren't tied to what we earn.
We sign a Business Associate Agreement. Claims data is encrypted, access-controlled, and never shared.
Share your plan size, plan design, and top drugs. No claims data. We show where opportunities typically sit for a plan like yours.
If it's worth a closer look, we sign a BAA and request 12 to 24 months of pharmacy claims from your PBM or TPA.
We rank every opportunity by estimated savings, ease of implementation, and clinical impact.
We walk your HR, finance, and broker teams through the findings and leave you with clear next steps.
Your plan is entitled to its own claims data, and federal law prohibits PBM contract clauses that block access to it. We can help you make the request.
The critical data points, ranked, so you know exactly where to start the conversation with your PBM.
Request a previewWhich classes have lower-cost generic or therapeutic alternatives.
Estimated savings ranges calculated for your plan size.
Prior authorization requirements for every identified alternative.
Opportunities ranked by likely financial and clinical impact.
Plans typically find savings opportunities worth many times the cost of the analysis.
Talk to our teamA one-time, pharmacist-reviewed review of your drug spend with ranked savings opportunities. Flat fee.
Turn your analysis into specific asks for your PBM renewal or RFP, backed by your own data. Timed to your renewal.
Quarterly tracking of spend, new generics, and pricing changes so savings don't slip away. Annual subscription.
We work alongside benefits brokers, consultants, and TPAs on analyses for their self-funded clients. You keep the relationship; we bring independent, pharmacist-reviewed findings you can put in front of the client.
Independent pharmacy findings for renewal and RFP conversations.
A concrete cost-management service you can offer every self-funded client.
A clear view of where your drug dollar goes, without changing your advisors.
Decision support, not a mandate. We're an analytics service, not a clinical decision tool. Alternatives that look good on paper may not be right for every member. We surface the options and the tradeoffs; your clinical and benefits advisors make the calls.
Savings estimates are ranges. Actual results depend on your claims mix, PBM contract terms, and rebate arrangements.
Can't find your answer?
Contact us with any other questions.
No. The free preview uses your plan size, plan design, and top drugs. If it shows enough opportunity to look closer, we request 12 to 24 months of pharmacy claims from your PBM or TPA under a signed Business Associate Agreement.
Typically 4 to 6 weeks from the first call to the live readout, depending on how quickly your PBM or TPA delivers the claims data.
No. StreamRX has no financial relationship with any PBM: no commissions, no rebate sharing, no referral fees. Our only compensation is the fee your plan pays us.
Flat fee, scoped to your plan size and data. We never charge a percentage of savings, so our recommendations aren't tied to what we earn. Plans typically find savings opportunities worth many times the cost of the analysis.
Yes. We sign a Business Associate Agreement before receiving any claims data. Data is encrypted, access is restricted to the analysis team, and it is never shared or sold.
Not necessarily. Many opportunities can be addressed through formulary, plan design, or contract changes with your current PBM. The report shows you where to start that conversation.
Yes. Your plan is entitled to its own claims data, and federal law prohibits PBM contract clauses that block access to it. We can help you make the request.
Yes. We work alongside brokers, consultants, and TPAs on analyses for their self-funded clients, so they can bring independent, pharmacist-reviewed findings to renewal conversations.
Deep dives into the financial and operational mechanics of self-funded pharmacy plan design.
All articles
The Consolidated Appropriations Act, 2026 requires PBMs to pass through 100% of rebates to ERISA plans, disclose compensation, and report drug-level data. Here is what changes for self-funded employers, the 2028–2029 timeline, what the law does not do, and what to put in PBM contracts now.
Read article
Selecting and monitoring a PBM is an ERISA fiduciary act. Here is what the lawsuits against J&J, Wells Fargo, and JPMorgan mean, how the 2026 PBM law changes oversight, and what a prudent, documented pharmacy benefit process looks like.
Read article
Cost-plus pharmacies publish their pricing, and research shows big savings on some generics. Here is what the evidence says, the difference between plan savings and member savings, four ways self-funded plans use cost-plus, and the watch-outs.
Read article
Humira biosimilars now hold most of the market and Stelara biosimilars launched at deep discounts. Here is where adoption stands, why your plan may still pay brand-level prices, private-label biosimilars, and how to switch members well.
Read article
Specialty drugs are a small share of prescriptions but roughly half of pharmacy spend, and growing fastest. Here are the latest benchmarks and five practical levers: one budget, site of care, biosimilars, the specialty pharmacy channel, and clinical management.
Read article
Discover the 5 critical, multi-million dollar mistakes self-insured plan sponsors make with their pharmacy benefits, from GLP-1 overspend traps to PBM billing blind spots, and concrete strategies to mitigate them immediately.
Read article
Prescription drug costs are the fastest-growing line item in most employer health plans today. Discover the hidden economics of PBM plans, the brand-to-generic gap, the rebate trap, and steps to optimize your pharmacy spend.
Read articleStart with a free preview. Tell us about your plan and we'll show you where opportunities typically sit for a plan like yours.
